1 August 2023 in IEEE Transactions on Information Forensics and Security
Machine learning and neural networks have become increasingly popular solutions for encrypted malware traffic detection. They mine and learn complex traffic patterns, enabling detection by fitting boundaries between malware traffic and benign traffic. Compared with signature-based methods, they have higher scalability and flexibility. However, affected by the frequent variants and updates of malware, current methods suffer from a high false positive rate and do not work well for unknown malware traffic detection. It remains a critical task to achieve effective malware traffic detection. In this paper, we introduce CBSeq to address the above problems. CBSeq is a method that constructs a stable traffic representation, behavior sequence, to characterize attacking intent and achieve malware traffic detection. We novelly propose the channels with similar behavior as the detection object and extract side-channel content to construct behavior sequence. Unlike benign activities, the behavior sequences of malware and its variant’s traffic exhibit solid internal correlations. Moreover, we design the MSFormer, a powerful Transformer-based multi-sequence fusion classifier. It captures the internal similarity of behavior sequence, thereby distinguishing malware traffic from benign traffic. Our evaluations demonstrate that CBSeq performs effectively in various known malware traffic detection and exhibits superior performance in unknown malware traffic detection, outperforming state-of-the-art methods.
7 April 2021 in IEEE Transactions on Information Forensics and Security
Network trace signature matching is one reliable approach to detect active Remote Control Trojan, (RAT). Compared to statistical-based detection of malicious network traces in the face of known RATs, the signature-based method can achieve more stable performance and thus more reliability. However, with the development of encrypted technologies and disguise tricks, current methods suffer inaccurate signature descriptions and inflexible matching mechanisms. In this paper, we propose to tackle above problems by presenting MBTree, an approach to detect encryption RATs Command and Control (C&C) communication based on host-level network trace behavior. MBTree first models the RAT network behaviors as the malicious set by automatically building the multiple level tree, MLTree from distinctive network traces of each sample. Then, MBTree employs a detection algorithm to detect malicious network traces that are similar to any MLTrees in the malicious set. To illustrate the effectiveness of our proposed method, we adopt theoretical analysis of MBTree from the probability perspective. In addition, we have implemented MBTree to evaluate it on five datasets which are reorganized in a sophisticated manner for comprehensive assessment. The experimental results demonstrate the accurate and robust of MBTree, especially in the face of new emerging benign applications.
1 November 2013 in Current Medicinal Chemistry
A series of radiolabeled peptides have been designed and optimized for tumor-targeted peptide receptor radionuclide therapy (PRRT). Pre-clinical and clinical applications of PRRT have shown promising results on tumor response, overall survival, and quality of life in patients with several kinds of tumors. 90Y-DOTA-TOC and 177Lu-DOTA-TATE are two of the most common radiopharmaceuticals with symptomatic improvements and complete clinical data. In addition to somatostatin analogs, radiolabeled peptides have been developed to target the relative receptors overexpressed in the tumors, such as integrin αvβ3, gastrin-releasing peptide receptor (GRPR), melanocortin-1 receptor (MC1-R), cholecystokinin (CCK) receptor, and glucagon-like peptide-1 receptor (GLP-1R). Several strategies have been designed to improve the therapeutic efficacy of PRRT. For instance, radiolabeled peptides could be optimized by the amino acid modification and radionuclide selection. Healthy tissue protective agents and multi-cycle procedures could effectively decrease the side effects of PRRT. Furthermore, combination treatments, including PRRT combined with surgery, chemotherapeutic agents, or radiosensitizing agents could be applied to increase the effectiveness of PRRT. In this review, the current progress of peptide-based radiopharmaceuticals for tumor-targeted PRRT was summarized. Radiopharmaceuticals currently under clinical investigation were also described.
19 April 2023 in Computers & Security
12 December 2023 in Computers & Security